Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Principles of Drug Action01:24

Principles of Drug Action

7.8K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
7.8K
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

301
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
301
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.8K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

868
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
868
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiparametric MRI and imaging transcriptomics reveal molecular and cellular correlates of neurodegeneration in experimental Parkinsonism.

NPJ Parkinson's disease·2026
Same author

Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates α-synuclein-induced progression of parkinsonism.

Journal of neuroinflammation·2026
Same author

Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA.

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

Nigral Neuroinflammation and Dopaminergic Neurons in Parkinson's Disease and Atypical Parkinsonisms.

Annals of neurology·2025
Same author

Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions.

Neuron·2025
Same author

Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions.

Neuron·2024
Same journal

Cerebellum crus II cortical thickness as a cognitive brain reserve in Parkinson's disease.

Parkinsonism & related disorders·2026
Same journal

Serious games and virtual reality in Parkinson's disease rehabilitation: A systematic review of randomized controlled trials.

Parkinsonism & related disorders·2026
Same journal

Respiratory-swallow training in Parkinson's disease: Effects of a single session on swallowing safety and efficiency with exploratory comparisons of biofeedback.

Parkinsonism & related disorders·2026
Same journal

Levodopa responsive childhood-onset generalized dystonia with diaphragmatic involvement associated with an SPTBN2 variant.

Parkinsonism & related disorders·2026
Same journal

Approach to a case of Neuro-Gonadal disorder: Perrault syndrome.

Parkinsonism & related disorders·2026
Same journal

Parakinesia in Chorea: Why attribution of intention is misleading.

Parkinsonism & related disorders·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.9K

MSA: From basic mechanisms to experimental therapeutics.

Antonio Heras-Garvin1, Nadia Stefanova1

  • 1Division of Neurobiology, Department of Neurology, Medical University of Innsbruck, Austria.

Parkinsonism & Related Disorders
|February 2, 2020
PubMed
Summary
This summary is machine-generated.

Multiple system atrophy (MSA) is a rare neurodegenerative disease with no cure. This review covers MSA

Keywords:
Movement disordersMultiple system atrophyNeurodegenerationPreclinical modelsTherapeutic strategiesα-synuclein

More Related Videos

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
10:08

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies

Published on: July 20, 2022

2.4K
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

9.9K

Related Experiment Videos

Last Updated: Dec 29, 2025

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.9K
Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
10:08

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies

Published on: July 20, 2022

2.4K
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

9.9K

Area of Science:

  • Neuroscience
  • Pathology
  • Neurology

Background:

  • Multiple system atrophy (MSA) is a rare, fatal neurodegenerative disorder.
  • Characterized by progressive autonomic and motor dysfunction.
  • Pathologically defined by alpha-synuclein accumulation in oligodendrocytes.

Purpose of the Study:

  • To review current knowledge on MSA's etiopathogenesis and neuropathology.
  • To discuss preclinical models and therapeutic strategies for MSA.

Main Methods:

  • Literature review of preclinical models and patient studies.
  • Synthesis of current understanding of MSA pathogenesis.
  • Analysis of existing and planned disease-modifying therapies.

Main Results:

  • MSA pathogenesis involves alpha-synuclein aggregation and neuronal degeneration.
  • Etiology is multifactorial, with potential therapeutic targets identified.
  • Current treatments cannot halt or reverse MSA progression.

Conclusions:

  • Understanding MSA's complex etiology is crucial for developing novel therapies.
  • Further research into preclinical models and clinical trials is essential.
  • No cure currently exists, highlighting the need for effective disease-modifying treatments.